Explaining Immunotherapy, PD-L1 and PD-1

Dr. Edward Garon explains the role of immunotherapy, PD-L1 and PD-1 in lung cancer. For more information visit www.lung.org/immunotherapy.
Support for this educational program provided by Amgen, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Lilly Oncology, Merck, Novartis and Pfizer.

[@riveenhewawaduge3337]

What is the difference between the interaction of PD-1 and PD-L1 compared to PD-1 and the inhibitor which results in the activation of T cells? as both the inhibitor and the PD-L1 bind to PD-1, why are the interactions not similar?

[@HussainAli-io2ji]

How do you treat infusion reaction when having this immunotherapy?

[@achievegoal5189]

Can we take keytruda medicine if the PD-L1(22C3) by immunohistochemistry shows no staining in tumor cells and only in scanty lymphocytes with TPS score of 0% and CPS score of less than 1%.

[@arash4108]

Bro just revise beforehand!